Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Pharmacogenomics-Supported Psychotropic Prescribing Trial

Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged 18 years or older - The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated - The treating clinician thinks PGx testing can benefit and refers the patient to the study Who Should NOT Join This Trial: - Unwillingness to donate saliva samples for genetic analysis - History of liver or bone marrow (hematopoietic cell) transplantation - PGx testing results are already available - No personal health identification number (PHIN) is available Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Aged 18 years or older * The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated * The treating clinician thinks PGx testing can benefit and refers the patient to the study Exclusion Criteria: * Unwillingness to donate saliva samples for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplantation * PGx testing results are already available * No personal health identification number (PHIN) is available

Treatments Being Tested

DIAGNOSTIC_TEST

Pharmacogenetic Testing

Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.

Locations (2)

Shared Health Facilities
Winnipeg, Manitoba, Canada
University of Manitoba College of Pharmacy
Winnipeg, Manitoba, Canada